There were 296 press releases posted in the last 24 hours and 168,189 in the last 365 days.

Kane Biotech Announces First Quarter 2019 Earnings Conference Call and Business Update

Conference Call to be held Thursday, May 23 at 4:30pm ET

/EIN News/ -- WINNIPEG, Manitoba, May 16, 2019 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE), (the “Corporation” or “Kane Biotech”), a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, today announced that it will host a conference call and webcast on Thursday, May 23 at 4:30pm Eastern Time to discuss its financial results for the first quarter of 2019, in conjunction with the filing of its quarterly financial statements.

Marc Edwards, Chief Executive Officer, and Ray Dupuis, Chief Financial Officer, will host the call and provide an update on the Company’s strategy and initiatives. There will be a management Q&A session following the prepared remarks. To participate in the call, please refer to the below dial-in details.

Dial-In (Toll-Free): 1 877 268 9044
Dial-In (Toll): 1 706 679 2995
Audience Passcode: 6168182
Webcast Link:

A live and archived audio webcast of the conference call will be available on Kane Biotech’s investor relations page.

About Kane Biotech
Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The Corporation has a portfolio of biotechnologies, intellectual property (58 patents and patents pending, trade secrets and trademarks) and products developed by the Corporation’s own biofilm research expertise and acquired from leading research institutions. StrixNB(TM), DispersinB(R), Aledex(R), bluestem(TM), AloSera(TM), coactiv+(TM) and Kane(R) are trademarks of Kane Biotech Inc. The Corporation is listed on the TSX Venture Exchange under the symbol "KNE".

For more information, please visit, or contact:

Marc Edwards  
Chief Executive Officer  
Kane Biotech Inc.  
+1 (514) 910-6991
Ray Dupuis  
Chief Financial Officer  
Kane Biotech Inc.  
+1 (204) 298-2200
Joe Green  
US. Investor Relations  
Edison Inc.  
+1 (646) 653-7030
Laine Yonker  
US. Investor Relations  
Edison Inc.  
+1 (646) 653 7035

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Caution Regarding Forward-Looking Information
This press release contains certain statements regarding Kane Biotech Inc. that constitute forward-looking information under applicable securities law. These statements reflect management’s current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to, risks relating to the Company’s: (a) financial condition, including lack of significant revenues to date and reliance on equity and other financing; (b) business, including its early stage of development, government regulation, market acceptance for its products, rapid technological change and dependence on key personnel; (c) intellectual property including the ability of the Company to protect its intellectual property and dependence on its strategic partners; and (d) capital structure, including its lack of dividends on its common shares, volatility of the market price of its common shares and public company costs. Further information about these and other risks and uncertainties can be found in the disclosure documents filed by the Company with applicable securities regulatory authorities, available at The Company cautions that the foregoing list of factors that may affect future results is not exhaustive.

Kane Logo Cropped TransBG.png